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Abstract
Patients with estrogen receptor (ER)- positive breast cancer are less likely to achieve 
a pathological complete response (pCR) with neoadjuvant chemotherapy. 
Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemo-
therapy in these hormone- sensitive patients. Most patients with ER- positive breast 
cancer are postmenopausal, and therefore, generally older and less able to tolerate 
chemotherapy. We aimed to investigate the efficacy and safety of tailored neoadju-
vant endocrine and chemoendocrine therapy for postmenopausal breast cancer pa-
tients. Untreated patients with primary invasive ER- positive, HER2- negative, stage 
I- IIIA breast cancer, and Ki67 index ≤30% were enrolled. Patients received exemes-
tane 25 mg/d for 12 weeks. Based on clinical response and change in Ki67 index, 
assessed at 8- 12 weeks, patients with complete response (CR), partial response (PR) 
with Ki67 index ≤5% after treatment, or stable disease (SD) with Ki67 index ≤5% 
before and after treatment were defined as responders. For the subsequent 24 weeks, 
responders continued exemestane monotherapy (group A), and nonresponders re-
ceived exemestane 25 mg/d plus cyclophosphamide 50 mg/d (group B). The primary 
endpoint was clinical response at weeks 24 and 36. A total of 59 patients (median 
age, 69 years) started initial exemestane monotherapy. After exclusion of three pa-
tients who discontinued during this period, 56 remained enrolled to receive subse-
quent treatment. Clinical response rates (CR and PR) and 95% CI at weeks 24 and 36 
were 85% (12/14; 57.2%- 98.2%) and 71% (10/14; 41.9%- 91.6%), respectively, in 
group A; and 54% (23/42; 38.7%- 70.2%) and 71% (30/42; 55.4%- 84.3%), respec-
tively, in group B. At week 36, no significant difference was found in median Ki67 
index between the groups (3.5% and 4.0%). There were no treatment- related deaths. 
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1 |  INTRODUCTION
Neoadjuvant treatment for breast cancer aims to decrease the 
risk of distal recurrence and to downstage the tumor, thereby 
allowing less extensive surgery.1 It has been shown to be 
equivalent to adjuvant chemotherapy in terms of disease- free 
survival and overall survival.2 Prognosis was found to be sig-
nificantly improved for patients whose operative specimen 
showed a pathological complete response (pCR), and pCR 
is now recognized as a factor associated with improved out-
comes with neoadjuvant chemotherapy.
Neoadjuvant endocrine therapy may be more appropriate 
than neoadjuvant chemotherapy in patients with hormone 
receptor (HR)- positive breast cancer. These patients are less 
likely to achieve pCR with neoadjuvant chemotherapy.3-5 
Furthermore, most patients with HR- positive breast cancer 
are postmenopausal, and therefore, generally older and less 
able to tolerate chemotherapy.
Since the introduction of third- generation aromatase in-
hibitors (eg anastrozole, exemestane, and letrozole), several 
studies have been carried out to investigate the effects of 
neoadjuvant endocrine therapy on HR- positive breast can-
cer,6-12 and it has been shown that this therapy may be as 
effective as neoadjuvant chemotherapy in postmenopausal 
women with HR- positive breast cancer.12,13 A systemic re-
view and meta- analysis in 2016 concluded that neoadjuvant 
endocrine therapy had clinical and radiologic response rates 
that are similar to those of neoadjuvant chemotherapy, and is 
associated with less toxicity.14 Neoadjuvant chemoendocrine 
therapy has also been explored; the addition of metronomic 
cyclophosphamide (ie frequent administration of low- dose 
cyclophosphamide) to letrozole resulted in greater reduction 
of proliferation than with letrozole alone.15
However, a marker for the prediction of benefit from neo-
adjuvant endocrine or chemoendocrine therapy in patients 
with HR- positive breast cancer has yet to be established. 
One candidate predictive marker is Ki67, a nuclear protein 
expressed by proliferating cells, which is used as a prog-
nostic marker in various types of cancer, including breast 
cancer.16-19 In several studies, changes in Ki67 index were 
used to evaluate the effects of neoadjuvant chemotherapy on 
prognosis in breast cancer patients.20-22 However, few equiv-
alent studies have been carried out for neoadjuvant endocrine 
therapy.6,23,24 A Ki67- based scoring system has recently been 
developed to monitor the response to neoadjuvant endocrine 
therapy.25 We previously showed that 24 weeks’ neoadjuvant 
endocrine therapy with exemestane provided clinical benefits 
and significant decreases in Ki67 index in postmenopausal 
patients with HR- positive breast cancer.6 Notably, there was 
no progression of tumors with Ki67 index <15% at baseline.
In the present study, we investigated the efficacy and 
safety of initial neoadjuvant endocrine therapy with exemes-
tane alone in postmenopausal patients with HR- positive 
breast cancer. We then classified patients into responders 
and nonresponders based on clinical response and change in 
Ki67 index values in response to the initial therapy to evalu-
ate the efficacy and safety of subsequent neoadjuvant therapy 
(ie continued exemestane monotherapy in responders and 
exemestane plus cyclophosphamide in nonresponders). The 
usefulness of Ki67 index as a marker was also examined.
2 |  PATIENTS AND METHODS
2.1 | Study design and patients
In this multicenter, open- label, phase II study, patients were 
enrolled through central registration from eight institu-
tions across Japan. Untreated postmenopausal patients with 
primary invasive estrogen receptor (ER)- positive, human 
epidermal growth factor receptor 2 (HER2)- negative, stage 
I- IIIA (T1c- T3, N0- 2, M0) breast cancer, Ki67 index ≤30%, 
and Eastern Cooperative Oncology Group performance sta-
tus 0 or 1 were eligible. ER- positive status was confirmed by 
immunohistochemistry (percentage of positive- staining cells, 
≥1%). HER2- negative status was confirmed by either im-
munohistochemistry (score, 1+ or 0) or fluorescence in situ 
hybridization (HER2/centromeric probe for chromosome 17 
ratio, <1.8; or mean number of copies of the HER2 gene, <4 
per nucleus).
All patients had adequate hematologic, cardiac, hepatic, 
and renal function. For each patient, the attending physician 
had judged neoadjuvant endocrine therapy to be indicated, 
after consideration of other treatment options, including sur-
gery and neoadjuvant chemotherapy.
The study was carried out in accordance with the 
Declaration of Helsinki (1975, as revised in 2008) and the 
Ethical Guidelines for Clinical Research of the Ministry of 
Health, Labour and Welfare of Japan. The study protocol was 
We found that clinical response comparable to that of responders was achieved in 
nonresponders after addition of cyclophosphamide to the initial endocrine therapy.
K E Y W O R D S
aromatase inhibitors, breast neoplasms, Ki67 index, neoadjuvant therapy, postmenopause, tailored 
therapy
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reviewed and approved by the institutional review board of 
each participating institution, and written informed consent 
was obtained from all patients.
The study is registered with the University Hospital 
Medical Information Network Clinical Trials Registry (http://
www.umin.ac.jp/ctr/index-j.htm), with the unique trial num-
ber UMIN000004751. The Japan Breast Cancer Research 
Group trial number is JBCRG- 11CPA.
2.2 | Study treatment
Figure 1 shows the study design. Patients first received 
exemestane alone, at 25 mg/d, administered orally, for 
12 weeks. Response to this initial treatment, including ef-
fects on Ki67 index values, was assessed at 8- 12 weeks, 
and patients were registered for treatment for the subse-
quent 24 weeks as follows: responders continued to receive 
exemestane monotherapy (group A), whereas nonrespond-
ers were switched to combination therapy with exemes-
tane plus cyclophosphamide 50 mg/d, administered orally 
(group B). The continuation of exemestane therapy for 
nonresponders was considered potentially beneficial when 
used in combination with cyclophosphamide therapy at 
50 mg/d.
Responders were defined as patients with complete re-
sponse (CR), those with partial response (PR) and Ki67 
index ≤5% after treatment, and those with stable disease 
(SD) and Ki67 index ≤5% both before and after treat-
ment. Nonresponders were defined as patients with PR 
and Ki67 index >5% after treatment, and those with SD 
and Ki67 index >5% either before or after treatment. If 
Ki67 index could not be determined, patients with CR or 
PR were classed as responders, and patients with SD as 
nonresponders.
For patients with progressive disease (PD), the study 
treatment was discontinued because it was considered to have 
shown inadequate efficacy in the initial treatment period.
2.3 | Concomitant and poststudy therapy
Before the initiation of the neoadjuvant endocrine therapy, 
the status of axillary lymph node metastasis, whether or not 
sentinel lymph node biopsy was performed, and the estimated 
extent of mastectomy with least invasion were recorded. 
After the completion of the study treatment, the status of ax-
illary lymphadenectomy, whether or not sentinel lymph node 
biopsy was performed, and the actual extent of surgical re-
section were recorded.
After completion of the study treatment, patients with CR, 
PR, or SD continued to receive exemestane as postsurgery 
adjuvant therapy for a total of at least 5 years, including the 
presurgery treatment period. Also, postsurgery adjuvant che-
motherapy and radiation therapy were permitted.
2.4 | End points
The primary end point was clinical response at weeks 24 and 
36. Secondary end points included pathological response; 
change in tumor size; changes in Ki67 index and preopera-
tive endocrine prognostic index (PEPI) scores derived from 
the pT stage, pN stage, Ki67 level, and ER status of the sur-
gical specimen;26 clinical benefit, assessed as increased rate 
of conversion from mastectomy to breast- conserving surgery 
(BCS); and incidence of adverse events (AEs). AEs were de-
fined as the occurrence or worsening in a patient who received 
the study treatment of subjective or objective symptoms, or 
an abnormal change in laboratory test values, that does not 
necessarily have a causal relationship with the study drug.
2.5 | Efficacy evaluation
Efficacy was evaluated in accordance with the Response 
Evaluation Criteria in Solid Tumors, version 1.1. Tumors 
were assessed at baseline and at 8- 12, 24, and 36 weeks. 
Additionally to visual inspection and palpation of the breast, 
F I G U R E  1  Study design. †Responders 
were defined as patients with complete 
response, partial response with Ki67 index 
<5% after treatment, or stable disease with 
Ki67 index <5% before and after treatment. 
PD, progressive disease
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tumor size was determined by imaging study (ultrasound; 
computed tomography, CT; or magnetic resonance imaging, 
MRI). The choice of imaging study was at the discretion of 
the attending physician, except for the requirement that CT 
or MRI had to be carried out additionally to ultrasound for 
tumors with maximum diameter >4 cm. In cases of multiple 
tumors, up to five tumors were selected for measurement.
Determination of clinical response was based on com-
parison of the maximum diameter of tumor(s) with corre-
sponding baseline measurements, or the development of new 
lesions, as follows: CR, 100% reduction in tumor size; PR, 
≥30% reduction in tumor size; PD, ≥20% increase in tumor 
size, or the development of one or more new lesions; and SD, 
not CR, PR, or PD. Clinical response rate was defined as the 
sum of percentages of patients with CR or PR.
Pathological response was determined centrally by the pathol-
ogy committee (as detailed in the below section), and categorized 
using the modified criteria previously described by Miller et al24 
as follows: pCR, when there was no evidence of malignant cell 
at the original tumor site; pathological partial response (pPR), 
when histological decrement in cellularity and or increment in 
fibrosis was detected; or no response, when there was no change.
2.6 | Procedures of pathological assessment
Tissue samples obtained by core needle biopsy were fixed in 
10% formalin (fixation time, 18- 24 hours), and serial 4- μm 
paraffin- embedded sections prepared from selected blocks. 
For each patient, an unstained slide was sent from each study 
site to a central laboratory (Tohoku University, Department of 
Pathology) for immunohistochemical staining to immunolo-
calize ER, PgR, HER2, and Ki67, as described previously.27-29
Tissue samples obtained before the start of the study 
treatment (for diagnostic purposes) were assessed by the 
pathological committee. The committee determined patho-
logical response after the initial exemestane monotherapy 
and at the completion of the study treatment using oper-
ative specimens. Additionally, tissue samples collected at 
8- 12 weeks were used for interim assessment of Ki67 index.
Ki67 index ≤5% and >5% were considered to indicate low 
and high tumor proliferation, respectively. The cutpoint of 5% 
was based on the results of a previous study, in which there 
was no progression of tumors with Ki67 index <15%, and 
in patients who achieved pPR, median Ki67 index decreased 
from 10 (range, 0- 55) to 2 (0- 34), that is ≤5%, after 24 weeks 
of exemestane therapy.6 Therefore, we chose Ki67 index ≤5% 
and favourable clinical response to the initial treatment as the 
criteria for continuation of exemestane monotherapy.
2.7 | Safety evaluation
Adverse events were recorded every 4 weeks during the 
treatment period and graded in accordance with the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events, version 4.0 (Japanese Clinical Oncology Group 
edition).30
2.8 | Statistical analyses
The target sample size was set as 55 patients. This was 
based partly on the results of calculations using Fleming’s 
single- stage design for phase II trials (α = 0.05; power, 
80%), with a threshold response rate of 54% and an ex-
pected response rate of 81% in group A, and a threshold 
response rate of 26% and an expected response rate of 54% 
in group B. Also included in the determination of target 
sample size were response rates achieved in previous stud-
ies after 8 weeks of neoadjuvant endocrine therapy with 
aromatase inhibitors, as well as assumptions about the pro-
portion of patients with Ki67 index ≤5% both before and 
after exemestane therapy, the proportion with Ki67 index 
reduced to ≤5% after exemestane therapy, and the number 
of dropouts.
Tumor response was evaluated by summary statistics; 
clinical response rate and 95% confidence intervals (CIs) 
were calculated. The Mann- Whitney U- test was used to 
compare continuous variables between groups A and B. 
McNemar’s test was used to compare clinical response rate 
at weeks 24 and 36. The distribution of AEs was summa-
rized and their incidence rates calculated, stratified by se-
verity (grades 1- 4).
For the evaluation of efficacy, an intent- to- treat analysis 
was carried out; data from all eligible patients were used. The 
full analysis set was defined as data from all patients who 
had completed the initial period of treatment with exemes-
tane alone and who started subsequent therapy with either 
continued exemestane monotherapy or exemestane plus cy-
clophosphamide. Data from all patients who received at least 
one dose of the study drug were used in the safety analysis.
Factors associated with classification of patients into re-
sponders or nonresponders were identified by univariate and 
multivariate analyses.
Statistical analyses were performed using IBM SPSS 
Statistics 23.0 (IBM Corp., Armonk, NY, USA) and R version 
3.2.2 (R core team, R Foundation for Statistical Computing, 
Vienna, Austria).
2.9 | Follow- up
Follow- up of responders and nonresponders is ongoing to in-
vestigate the effects on survival in the longer term (disease- 
free survival and overall survival) of the tailored approach 
to neoadjuvant treatment of ER- positive breast cancer de-
scribed above. This has been specified in the protocol as a 
secondary endpoint, and further results will be published in 
due course.
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3 |  RESULTS
3.1 | Patients
Figure 2 shows patient disposition. A total of 63 patients were 
provisionally enrolled between January 2011 and July 2015. 
After exclusion of four patients because of violation of the 
eligibility criteria (Ki67 index >30%), 59 patients started the 
initial 12- week period of treatment with exemestane alone.
Table 1 shows the baseline characteristics of the 59 eli-
gible patients (intent- to- treat data set). All had ER- positive, 
HER2- negative breast cancer. None had received prior treat-
ment for breast cancer.
During the initial period of treatment with exemestane 
alone, three patients discontinued treatment. Of the remain-
ing 56, whose response to the initial treatment was assessed 
at 8- 12 weeks, 14 were classified as responders (PR and Ki67 
index ≤5% after treatment, nine patients; SD and Ki67 index 
≤5% both before and after treatment, five patients), and 42 
were classified as nonresponders (PR and Ki67 index >5% 
after treatment, three patients; SD and Ki67 index >5% either 
before or after treatment, 39 patients). Subsequent treatment, 
that is, continued exemestane monotherapy (in group A) or 
combination therapy with exemestane plus cyclophospha-
mide (in group B), was discontinued by two patients and six 
patients, respectively. One patient in each group decided not 
to undergo surgery, therefore, a total of 46 patients completed 
the study.
3.2 | Compliance
The rate of compliance, with or without dose reduction, was 
93% (13/14 patients) and 83% (35/42 patients) in groups A 
and B, respectively.
3.3 | Clinical response at 24 and 36 weeks 
(primary end point)
Clinical response rates (sum of the percentages of patients 
with CR or PR) at weeks 24 and 36 were 85% (12/14 pa-
tients, 95% CI 57.2%- 98.2%) and 71% (10/14 patients, 95% 
CI 41.9%- 91.6%), respectively, in group A, and 54% (23/42 
patients, 95% CI 38.7%- 70.2%) and 71% (30/42 patients, 95% 
CI 55.4%- 84.3%), respectively, in group B (Table 2). Clinical 
response rate at weeks 8- 12 was higher in group A than in 
group B (P = .00). In patients who responded to the initial 
treatment, clinical response rate remained high with contin-
ued exemestane monotherapy. In the nonresponders, clini-
cal response rate improved with subsequent treatment with 
exemestane plus cyclophosphamide.
3.4 | Change in tumor size
Figure 3 shows changes in tumor size in individual patients at 
8- 12 weeks and 36 weeks. Similar results were obtained with 
ultrasound (Figure 3A) and with CT or MRI (Figure 3B). 
F I G U R E  2  Patient disposition during the study. AE, adverse event
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Regarding the initial tumor regression at 8- 12 weeks, tumor 
size continued to decrease until 36 weeks in the majority of 
patients. Most group A patients achieved tumor regression at 
8- 12 weeks. Group B patients had a similar degree of tumor 
regression at 36 weeks.
3.5 | Change in Ki67 index
Figure 4 shows changes in median Ki67 index. Median Ki67 
index was significantly lower in responders to the initial 
treatment with exemestane alone than in nonresponders, both 
at baseline (4.6% vs 12.0%, P = .001) and at secondary reg-
istration (8- 12 weeks) (2.0% vs 2.3%, P = .013). However, 
there was no significant difference in median Ki67 index at 
36 weeks between group A and group B (3.5% and 4.0%, 
respectively).
Figure 5 shows patterns of change in Ki67 index in indi-
vidual patients over time. Of the patients who responded to 
the initial treatment with exemestane alone, Ki67 index de-
creased during this period in all except one patient, in whom 
Ki67 index showed a minimal increase. In one patient, the 
decrease was substantial (about 28%). Ki67 index either in-
creased or decreased during subsequent continued exemes-
tane monotherapy up until surgery but remained <10% in 
all except one patient. Of the nonresponders to exemestane 
monotherapy, Ki67 index decreased during the initial treat-
ment period in all except two patients. At the end of exemes-
tane monotherapy, four patients had Ki67 index >10%. Ki67 
index decreased further in three of these patients during 
subsequent exemestane plus cyclophosphamide therapy up 
until surgery. In four patients, Ki67 index increased to >20% 
during combination therapy, and in three of these patients the 
increase was substantial (about 20%- 40%).
3.6 | Factors associated with 
response or nonresponse to the initial therapy
The results of univariate and multivariate analyses carried 
out to identify factors associated with classification of pa-
tients into responders or nonresponders, based on clinical 
response and change in Ki67 index values in response to the 
initial therapy, are summarized in Table 3. Clinical nodal sta-
tus N1, ER Allred score 8, and pretreatment Ki67 index <14 
were associated with increased likelihood of classification as 
a responder.
3.7 | Change in preoperative endocrine 
prognostic index
The proportion of patients with PEPI score of 0 was similar 
in group A (3/14 patients, 21%) and group B (10/42 patients, 
T A B L E  1  Baseline patient characteristics (n = 59)a
Characteristic n (%)b
Age, y (median and range) 69 (53- 86)
Tumor stage
T1 8 (14)
T2 49 (83)
T3 2 (3)
Nodal status
N0 50 (85)
N1 9 (15)
Clinical stage
I 4 (6)
IIA 49 (83)
IIB 5 (8)
IIIA 1 (2)
PgR status
Positive 50 (85)
Negative 9 (15)
Ki67 index status
≤10 32 (54)
>10, ≤20 15 (26)
>20, ≤30 12 (20)
PgR, progesterone receptor.
aIntent- to- treat data set. For patients with multiple tumors, the data are for repre-
sentative lesions only.
bUnless otherwise indicated.
Time (weeks)
Group A (continued exemestane 
monotherapy)
Group B (exemestane plus 
cyclophosphamide)
n (%) 95% CI (%) n (%) 95% CI (%)
8- 12 9/14 (64) 35.1- 87.2 3/42 (7) 1.5- 19.5
24b 12/14 (85) 57.2- 98.2 23/42 (54) 38.7- 70.2
36b 10/14 (71) 41.9- 91.6 30/42 (71) 55.4- 84.3
aClinical response rate defined as the sum of the percentages of patients with complete response or partial 
response.
bNo significant difference was found between clinical response rate at weeks 24 and 36 for either group A or 
group B (McNemar’s test).
T A B L E  2  Changes in clinical 
response rate over the course of the studya
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23%). There was no significant difference in PEPI score be-
tween the groups (Table 4).
3.8 | Pathological response
In group A, 1 patient had pCR, 12 had pPR, and there were no 
nonresponders. In group B, 2 patients had pCR, 30 had pPR, 
and 7 were nonresponders. There was no significant differ-
ence in pCR rate between groups A and B (Table 5).
3.9 | Breast- conserving surgery rate
No increased rate of conversion to BCS was found either in 
all eligible patients who received exemestane- based therapy 
or in the separate groups (data not shown). Based on assess-
ments made before treatment with exemestane, total mas-
tectomy was indicated for 3/14 patients and BCS for 11/14 
patients in group A. In group B, total mastectomy was in-
dicated for 10/42 patients and BCS for 32/42 patients. At 
F I G U R E  3  Waterfall plots showing 
clinical response to exemestane- based 
neoadjuvant therapy at 8- 12 weeks and 
36 weeks in patients who responded to initial 
treatment with exemestane alone and who 
continued to receive monotherapy (group 
A), and non- responders, who were switched 
to exemestane plus cyclophosphamide 
(group B). Results obtained by (A) 
ultrasound and (B) computed tomography or 
magnetic resonance imaging. The horizontal 
axes indicate paired data from individual 
patients for whom data were available. The 
vertical axes show percentage change in 
tumor size from baseline; positive values 
indicate tumor progression, and negative 
values indicate tumor regression
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completion of the study treatment, the proportion of patients 
who underwent BCS was 71% (10/14 patients) in group A 
and 69% (29/42 patients) in group B.
3.10 | Adverse events
There were no treatment- related deaths. Treatment was dis-
continued due to elevated liver enzyme in one patient in 
group B. Other AEs were manageable (Table 6).
4 |  DISCUSSION
Our main objectives were to investigate, in postmenopau-
sal patients with ER- positive breast cancer and Ki67 index 
≤30%, first, the efficacy and safety of neoadjuvant endocrine 
therapy with exemestane alone; and second, the efficacy and 
safety of subsequent neoadjuvant chemoendocrine therapy 
with exemestane in combination with low- dose cyclophos-
phamide in patients who do not respond to exemestane 
monotherapy.
A predictive biomarker has yet to be established for use 
in optimizing the neoadjuvant treatment strategy for individ-
ual patients with ER- positive breast cancer. One candidate is 
Ki67, which is a prognostic marker in breast cancer.16 Low 
and high Ki67 index values indicate low and high tumor 
proliferation, respectively. In a previous study of neoadju-
vant exemestane therapy for primary breast cancer, median 
Ki67 index decreased from 9 (range, 0- 47) to 2 (range, 0- 37) 
in patients who achieved PR, and from 8 (range, 1- 68) to 
3 (range, 0- 51) in patients with SD.6 Additionally, patients 
with SD had a similar prognosis to those with PR, and post-
treatment Ki67 had prognostic value.31 Because of our in-
terest in change in Ki67 index as an indicator of treatment 
efficacy, we chose in the present study to classify patients 
F I G U R E  4  Change in median Ki67 index in patients who 
responded to initial treatment with exemestane alone and who 
continued to receive exemestane monotherapy (group A), and 
non- responders, who were switched to combination therapy with 
exemestane plus cyclophosphamide (group B). Data from the full 
analysis set. * stands for extreme outliers
F I G U R E  5  Change in Ki67 index over the course of the study in individual patients in (A) group A (continued exemestane monotherapy) and 
(B) group B (exemestane plus cyclophosphamide). Baseline data from the full analysis set
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T A B L E  3  Factors associated with response or non- response to the initial therapy
A. Univariate analysis
Factor B SE P ORa 95% CI
Age −0.003 0.05 .95 1.00 0.91- 1.09
≥T2 (ref: T1) −0.56 1.14 .62 0.57 0.06- 5.34
N1 (ref: N0) −1.66 0.77 .03 0.19 0.04- 0.85
ER Allred score 8 
(ref: <8)
−1.10 0.83 .19 0.33 0.07- 1.70
PgR positive  
(ref: negative)
0.00 0.88 1.00 1.00 0.18- 5.63
HER2 2+  
(ref: negative)
−1.65 0.84 .05 0.19 0.04- 1.00
Ki67 index 0.17 0.07 .02 1.19 1.03- 1.37
Ki67 index ≥14  
(ref: <14)
2.37 1.08 .03 10.74 1.29- 89.72
B. Multivariate analysis
Factor B SE P ORa 95% CI
Model 
P
Cox- Snell 
R2
Starting model .007 0.29
Age 0.03 0.06 .58 1.03 0.92- 1.18
≥T2 (ref: 
T1)
−2.28 1.71 .12 0.10 0.00- 1.57
N1 (ref: N0) −3.84 1.70 .002 0.02 0.00- 0.31
ER Allred 
score 8 
(ref: <8)
−2.32 1.53 .06 0.10 0.001- 1.08
PgR 
positive 
(ref: 
negative)
−0.92 1.25 .43 0.40 0.02- 3.39
HER2 2+ 
(ref: 
negative)
−0.59 1.02 .54 0.55 0.08- 4.07
Ki67 index 
≥14 (ref: 
<14)
1.90 0.98 .03 6.66 1.22- 79.30
Best- fit model .001 0.29
≥T2 (ref: 
T1)
−2.78 1.78 .06 0.06 0.00- 1.06
N1 (ref: N0) −4.41 1.94 .001 0.01 0.00- 0.24
ER Allred 
score 8 
(ref: <8)
−2.76 1.67 .02 0.06 0.00- 0.72
Ki67 index 
≥14 (ref: 
<14)
1.89 0.98 .02 6.59 1.25- 68.35
CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OR, odds ratio; PgR, progesterone receptor; ref, reference category; 
SE, standard error.
aOdds ratios for non- response.
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as responders or nonresponders based primarily on change 
in Ki67 index values and secondarily on clinical response. 
Thus, patients with Ki67 index ≤5% both before and after 
treatment were classified as responders despite having SD, 
and patients with Ki67 index >5% after treatment were clas-
sified as nonresponders despite achieving PR. We believe 
that Ki67 index value is sufficiently informative to guide 
clinical decision making for patients with hormone receptor- 
positive breast cancer, because triaging breast cancer pa-
tients to neoadjuvant chemotherapy on the basis of Ki67 
index >10% after neoadjuvant aromatase inhibitor treatment 
has been shown to be feasible.32
The high clinical response rate achieved in patients who 
responded to initial therapy with exemestane alone was 
maintained with continued exemestane monotherapy, and 
the great majority experienced tumor regression at 36 weeks. 
These findings add to evidence for the efficacy of ≥24 weeks 
of neoadjuvant exemestane monotherapy.6 In nonresponders, 
clinical response rate improved after the switch to chemoen-
docrine therapy, and tumor regression was almost universal 
in this group too. The addition of low- dose cyclophospha-
mide may have potentiated the effects of exemestane by in-
hibition of angiogenesis and vasculogenesis.15,33 Regarding 
safety, exemestane- based therapy seems to be well tolerated.
Exemestane- based therapy reduced tumor proliferation. 
In the first 12 weeks of treatment, substantial decreases 
in Ki67 index were found in individual patients. Marked 
decreases in Ki67 expression have also been reported in 
patients treated with other aromatase inhibitors, including 
letrozole24,34,35 and anastrozole.23,36 In patients who were 
later assessed as having responded to the initial period of 
exemestane monotherapy, median Ki67 index was signifi-
cantly lower than in nonresponders both before treatment 
and at secondary registration (8- 12 weeks). However, me-
dian Ki67 index was similar in both groups at 36 weeks. It 
is plausible that tumors with low proliferation, as indicated 
by low Ki67 index both before treatment and at secondary 
registration, are more likely to decrease in size with contin-
ued exemestane monotherapy.
PEPI (based on Ki67 index) is a validated tool for predic-
tion of relapse risk in women with early- stage ER- positive 
breast cancer after neoadjuvant endocrine therapy.26,37 PEPI 
scores enable clinicians to tailor subsequent therapy accord-
ing to risk of relapse, thereby avoiding the use of chemother-
apy in low- risk patients. The American College of Surgeons 
Oncology Group Z1031A trial is one of the latest to provide 
support for the assessment of prognosis based on tumor char-
acteristics after neoadjuvant endocrine therapy in postmeno-
pausal women with ER- positive breast cancer.32 Ki67 index 
was used to decide subsequent treatment after 2- 4 weeks of 
neoadjuvant therapy with an aromatase inhibitor (anastrozole, 
exemestane, or letrozole); patients with Ki67 index >10% 
were switched to neoadjuvant chemotherapy. Risk of relapse 
over a median of 5.5 years’ follow- up was significantly lower 
in patients with a PEPI score of 0 than in those with PEPI >0 
(3.7%, 4/109, vs 14.4%, 49/341). The very low risk of relapse 
(3.6%) in patients with a PEPI score of 0 and treated without 
chemotherapy suggests that adjuvant endocrine monotherapy 
may be appropriate in this group. Interestingly, the proportion 
of patients with PEPI score of 0 in the present study (group 
PEPI score
Group A  
(continued exemestane  
monotherapy), n (%)
Group B  
(exemestane plus  
cyclophosphamide), n (%)
0 3/14 (21) 10/42 (23)
1- 3 6/14 (62) 21/42 (50)
≥4 4/14 (28) 7/42 (16)
NE 1/14 (7) 4/42 (9)
NE, not evaluable.
T A B L E  4  Association between 
treatment group and preoperative endocrine 
prognostic index (PEPI) score
T A B L E  5  Pathological response
Pathological response
Group A  
(continued exemestane  
monotherapy), n (%)
Group B  
(exemestane plus  
cyclophosphamide), n (%)
Both groups,  
n (%)
P (group A 
vs group B)
Pathological complete 
response
1 (7) 1 (2) 2 (4) .5
Pathological partial  
response
12 (86) 31 (74) 43 (77)
No response 0 (0) 7 (17) 7 (13)
Untested 1 (7) 3 (7) 4 (7)
Total 14 (100) 42 (100) 56 (100)
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A, 21%; group B, 23%) was similar to the proportion in the 
IMPACT trial (21%) and the POL trial (28%). Further long- 
term follow- up is needed to clarify whether risk of relapse is 
lower in our patients with a PEPI score of 0, and whether the 
addition of cyclophosphamide to exemestane therapy affects 
outcome in these patients.
One aim of neoadjuvant therapy is to increase the likeli-
hood of patients undergoing BCS rather than total mastec-
tomy. However, we found no strong evidence for this in either 
the responders or the nonresponders, despite the evidence of 
tumor regression. This contrasts with the findings of previous 
studies of neoadjuvant therapy using aromatase inhibitors in 
postmenopausal breast cancer patients.6-9,38
In the present study, at completion of the study treatment, a 
relatively high proportion of patients underwent BCS (around 
70% in each group). Previous studies have shown that neoad-
juvant endocrine therapy improves operability and increases 
the rate of conversion from mastectomy to BCS; however, 
they included patients with more advanced disease, that is, 
those who were ineligible for BCS or who had cancer that was 
inoperable by standard mastectomy. This may explain why no 
increased rate of conversion to BCS was found in our study, 
either in the whole group (all eligible patients who received 
exemestane- based therapy) or the individual groups.
The finding that neoadjuvant therapy had no significant 
effect on the rate of conversion from mastectomy to BCS in 
our study, despite the evidence of tumor regression, raises 
the question of whether neoadjuvant exemestane therapy is 
needed in postmenopausal patients with hormone- sensitive 
breast cancer. However, we believe that a tailored approach 
to neoadjuvant treatment of ER- positive breast cancer is ben-
eficial. Classification of patients into responders and non-
responders, based on clinical response and change in Ki67 
index values in response to the initial therapy, enables iden-
tification of patients for whom treatment with exemestane 
alone is more likely to be successful, thereby sparing them 
the unpleasant effects of chemotherapy.
The results of univariate and multivariate analyses showed 
clinical nodal status (N1), high ER Allred score and low prolif-
eration to be associated with increased likelihood of response 
to the initial therapy. Therefore classification of patients into 
responders or nonresponders, based on clinical response and 
change in Ki67 index values in response to the initial therapy, 
seems to reflect biological characteristics rather than tumor 
volume expressed by clinical nodal status. To help predict 
long- term outcomes, PEPI score could be used.
To the best of our knowledge, the present study is the first 
to investigate the efficacy and safety of combination therapy 
with exemestane and low- dose cyclophosphamide in cases of 
failure to respond to initial treatment with exemestane alone.
The present study has several limitations. First, the study 
population was limited to 59 eligible patients. Second, al-
though we used a single laboratory for immunohistochemi-
cal staining to avoid the problem of variability in Ki67 index 
T A B L E  6  Major adverse events during the treatment perioda
Total (n = 56)
Group A  
(continued exemestane 
monotherapy) (n = 14)
Group B  
 (exemestane plus  
 cyclophosphamide) (n = 42)
Grade ≥3 All grades Grade ≥3 All grades Grade ≥3 All grades
All adverse events 7 (13) 30 (54) 1 (7) 3 (21) 6 (14) 27 (64)
Leukopenia 0 (0) 5 (9) 0 (0) 0 (0) 0 (0) 5 (12)
Increased ALT 3 (5) 4 (7) 0 (0) 0 (0) 3 (7) 4 (10)
Increased ALP 0 (0) 3 (5) 0 (0) 0 (0) 0 (0) 3 (7)
Increased AST 0 (0) 3 (5) 0 (0) 0 (0) 0 (0) 3 (7)
Increased γ- GTP 2 (4) 2 (4) 0 (0) 0 (0) 2 (5) 2 (5)
Hypertension 1 (2) 2 (4) 1 (7) 1 (7) 0 (0) 1 (2)
Arthralgia 1 (2) 2 (4) 0 (0) 1 (7) 1 (2) 1 (2)
Bladder infection 0 (0) 2 (4) 0 (0) 0 (0) 0 (0) 2 (5)
Hepatobiliary disorders 
(elevated liver enzyme)
0 (0) 1 (2) 0 (0) 1 (7) 0 (0) 0 (0)
Nausea 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (2)
Diarrhea 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (2)
Osteoporosis 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (2)
Gastritis 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (2)
Hypertriglyceridaemia 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (2)
ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate transaminase; γ- GTP, γ- glutamyl transpeptidase.
aValues are expressed as the number (%).
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measurement across laboratories,39 intralaboratory vari-
ability remained a possibility. Third, the 83% rate of com-
pliance in group B may have influenced outcomes in this 
group. Finally, PEPI scores were originally derived from the 
pT stage, pN stage, Ki67 level, and ER status of the surgical 
specimen after the initial treatment with aromatase inhibitor 
alone, and not after aromatase inhibitor plus chemotherapy 
(ie cyclophosphamide).
5 |  CONCLUSIONS
Our findings provide support for the potential benefit of a tai-
lored approach to neoadjuvant treatment of ER- positive breast 
cancer, in which postmenopausal patients with inadequate 
response (clinical and biologic, ie change in Ki67 index) to 
initial endocrine therapy are switched to chemoendocrine ther-
apy, thereby maximizing therapeutic effects while minimizing 
the incidence of AEs associated chemotherapeutic drugs.
Trial number: UMIN000004751 (UMIN Clinical Trials 
Registry).
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